These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29486966)
1. Radiosynthesis and biological evaluation of Huang S; Han Y; Chen M; Hu K; Qi Y; Sun P; Wang M; Wu H; Li G; Wang Q; Du Z; Zhang K; Zhao S; Zheng X Bioorg Med Chem Lett; 2018 Apr; 28(6):1143-1148. PubMed ID: 29486966 [TBL] [Abstract][Full Text] [Related]
2. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents. Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040 [TBL] [Abstract][Full Text] [Related]
3. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221 [TBL] [Abstract][Full Text] [Related]
4. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines. Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465 [TBL] [Abstract][Full Text] [Related]
7. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity. Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919 [TBL] [Abstract][Full Text] [Related]
8. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and preliminary evaluation of Lu X; Wang C; Li X; Gu P; Jia L; Zhang L Bioorg Med Chem; 2019 Feb; 27(3):545-551. PubMed ID: 30611635 [TBL] [Abstract][Full Text] [Related]
10. Jain A; Kameswaran M; Pandey U; Prabhash K; Sarma HD; Dash A Bioorg Med Chem Lett; 2017 Oct; 27(19):4552-4557. PubMed ID: 28893469 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors. Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528 [TBL] [Abstract][Full Text] [Related]
12. Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. Slobbe P; Windhorst AD; Stigter-van Walsum M; Schuit RC; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ Nucl Med Biol; 2014 Oct; 41(9):749-57. PubMed ID: 25066021 [TBL] [Abstract][Full Text] [Related]
13. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063 [TBL] [Abstract][Full Text] [Related]
15. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy. Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801 [TBL] [Abstract][Full Text] [Related]
16. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts. Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529 [TBL] [Abstract][Full Text] [Related]
18. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients. Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. Rao GW; Xu GJ; Wang J; Jiang XL; Li HB ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754 [TBL] [Abstract][Full Text] [Related]
20. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]